Irbesartan Amarox

Irbesartan, the active ingredient in Irbesartan Amarox, is an angiotensin II receptor blocker presented as an oral tablet for oral use. It is employed to lower high blood pressure and to protect kidney function in patients with diabetic nephropathy.

GNH USA supplies Irbesartan Amarox as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support global distribution. Customers benefit from reliable supply chains, competitive pricing, and responsive technical support.

Irbesartan is an angiotensin II receptor blocker used to manage conditions related to the renin‑angiotensin system.

Hypertension: lowers systolic and diastolic blood pressure in patients with elevated readings. Diabetic nephropathy: slows progression of kidney damage in patients with type 2 diabetes. Chronic kidney disease: helps preserve renal function in patients with CKD associated with hypertension.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue - Abdominal discomfort - Elevated blood potassium levels - Mild cough

Serious or Rare Side Effects: - Angioedema (swelling of face, lips, tongue) - Severe hypotension - Acute kidney injury or worsening renal function - Hepatic injury (elevated liver enzymes) - Neutropenia or other blood dyscrasias

Before initiating therapy, clinicians should consider several safety aspects.

Monitor blood pressure: adjust dose based on response. Assess renal function: check serum creatinine and potassium before starting and periodically during treatment. Avoid use in patients with known hypersensitivity to irbesartan or other ARBs. Caution in severe hepatic impairment: may require dose adjustment. Pregnancy: contraindicated in the second and third trimesters due to fetal risk. Store at room temperature: keep in the original container, protect from moisture and light.

Irbesartan may interact with several medicines; interactions are categorized by clinical significance.

Major Interactions (Avoid): - Potassium‑sparing diuretics: risk of hyperkalaemia. - ACE inhibitors or aliskiren (in diabetes): increased risk of renal dysfunction and hyperkalaemia. - NSAIDs: may diminish antihypertensive effect and impair renal function.

Moderate Interactions (Monitor Closely): - Lithium: irbesartan can raise lithium concentrations. - Cyclosporine: may increase serum creatinine. - Beta‑blockers: additive blood‑pressure‑lowering effect.